Coastar Therapeutics

Pre-clinical

San Diego, United StatesFounded 2021coastartherapeutics.com

Coastar Therapeutics is developing a novel biological payload delivery platform to overcome key challenges in genetic medicine, specifically immune clearance and lack of targeting. The company's core technology leverages engineered red blood cell membranes to create a stealthy, targeted delivery vehicle for a range of genetic payloads. Coastar is actively engaging with global partners and has gained recognition as an innovative startup, evidenced by its selection as a 2025 'Cool Company' and participation in major industry conferences like BIOCOM 2026.

Founded

2021

Focus

Drug DeliveryNanotechnology

AI Company Overview

Technology Platform

An Erythrocyte Derived Membrane (EDM) based gene delivery platform designed to protect genetic medicines (DNA, RNA, viral vectors) from immune clearance and enable precision targeting for scalable in vivo delivery.

Opportunities

The massive and growing genetic medicine market creates a significant opportunity for a superior delivery platform.

Coastar's EDM technology could enable partnerships across multiple therapeutic areas, allowing the company to benefit from the success of various drug developers without bearing the full risk of drug discovery itself.

Risk Factors

Key risks include the high technical uncertainty of translating its novel EDM platform into a clinically viable product, intense competition from established delivery technologies, and dependency on securing sufficient funding and strategic partnerships to advance development.

Competitive Landscape

Coastar competes with established lipid nanoparticle companies (e.g., Moderna, BioNTech) and other bio-inspired delivery startups (e.g., exosome-focused firms). Its differentiation hinges on proving its erythrocyte-derived membrane platform offers superior immune evasion, targeting, and safety compared to existing non-viral delivery systems.